جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

3 مُخرَج نتائج البحث عن «Janus kinase»

مراجعةوصول مفتوح2026

Therapeutic Outcomes of Janus Kinase Inhibitors in Refractory Nail Lichen Planus: A Systematic Review

Cureus · مجلد 18 (5) · e108953-e108953

Nail lichen planus (NLP) is a chronic immune-mediated inflammatory disorder and one of the most challenging forms of lichen planus to treat. Conventional therapies, including intralesional corticosteroids, systemic immunosuppressants, and topical agents, are often associated with high failure rates and significant adverse effects. Janus kinase inhibitors (JAKIs) have emerged as mechanistically rational therapeutic agents because of the central role of the interferon (IFN)-JAK-signal transducer and activator of transcription (JAK-STAT) pathway in lichenoid inflammation; however, their efficacy and safety in NLP have not yet been systematically evaluated. A systematic review was conducted by searching PubMed, Scopus, and Web of Science from database inception through March 2026 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Eligible studies included patients with clinically and/or histopathologically confirmed NLP and studies reporting original patient-level data of any design. Risk of bias was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools appropriate to each study design. A cumulative time-to-response model was constructed, and a random-effects meta-analysis of standardized mean change (SMC) in nail severity scores was performed where data permitted. Thirteen studies were included with a total of 25 patients. Interventions included oral and topical tofacitinib, baricitinib, abrocitinib, upadacitinib, and topical ruxolitinib. Clinically meaningful improvement was reported across all studies, with most responses occurring within three to seven months of treatment initiation. The pooled SMC was 1.65 (95% confidence interval (CI): 0-3.59), with substantial heterogeneity (I²=87.6%). No serious adverse events were reported. Overall, JAKIs appear to be effective and well tolerated in the short term for refractory NLP, supporting their potential role as rescue therapy in selected cases. However, the current evidence remains limited and heterogeneous, underscoring the need for prospective randomized controlled trials with standardized outcome measures and longer follow-up durations.

nail lichen planusJAK inhibitorsrefractory lichen planustofacitinib
مراجعةمفتوح (مستودع)2025

Efficacy and Safety of Tofacitinib for Vitiligo: A Systematic Review

Saudi Medical Horizons Journal · مجلد 5 (1) · 42-49

The main objective of this study was to evaluate and summarize the available clinical evidence on the efficacy and safety of tofacitinib for the treatment of vitiligo. A thorough search across four databases identified 416 relevant publications. After removing duplicates using Rayyan QCRI and assessing their relevance, 204 full-text articles were reviewed, and ultimately, five studies met the criteria for inclusion were included. A total of 121 vitiligo patients were included; less than half of them 52 (43%) were males. Findings indicate that while tofacitinib alone has limited effectiveness, its combination with narrowband-ultraviolet B (NBUVB) phototherapy significantly enhances repigmentation, particularly in refractory cases, including acral lesions. Micro-focused UVB phototherapy also demonstrates high efficacy, with further improvements observed when paired with tofacitinib. However, a 16-week treatment duration may be insufficient for patients with inadequate responses to prior therapies, suggesting the need for higher doses or extended treatment periods. This makes a combination of tofacitinib and phototherapy promising as a therapeutic strategy against vitiligo, with cases resistant to all the modalities of standard therapy. As promising as these results read with significant repigmentation, full optimization of treatment duration and dosage will be imperative. These findings need to be further confirmed in future large, randomized controlled trials and long-term outcomes evaluated to definitely establish a standardized protocol for vitiligo management. These efforts will be essential to fully realize the potential of Janus kinase (JAK) inhibitors as part of a comprehensive, targeted approach to the management of vitiligo.

tofacitinibvitiligoJAK inhibitorsnarrowband UVB phototherapy
مقالوصول مغلق201838استشهاد

Renoprotective effect of nifuroxazide in diabetes-induced nephropathy: impact on NFκB, oxidative stress, and apoptosis

Toxicology Mechanisms and Methods · مجلد 28 (6) · 467-473

The prevalence of diabetes mellitus (DM) is drastically increased worldwide. Diabetic nephropathy (DN) is a microvascular complication of DM and a common cause of end stage renal disease (ESRD). DN has been recently reported as the most common cause among ESRD patients. Shortage of a definitive cure for DN and the social and economic burden of this disease provide considerable impetus for development of new therapies. In the present study, we evaluated the effect of nifuroxazide, a potent inhibitor of Janus kinase/signal transducers and activators of transcription (JAK2/STAT3), on nuclear factor kappa B (NFκB), oxidative stress, and apoptosis in diabetic kidney. Following induction of diabetes by single dose of streptozotocin (50 mg/kg), nifuroxazide was administrated to diabetic rats (25 mg/kg/day, orally) for 8 weeks. Our results showed that nifuroxazide treatment, attenuated diabetes-induced damage in renal structure, ameliorated oxidative stress, triggered antioxidant defense, reduced NFκB nuclear translocation and cleaved caspase-3 expression and down regulated the activity of apoptotic enzymes (caspase-3/caspase-8/caspase-9) in diabetic kidney. In conclusion, nifuroxazide exhibited renoprotective effect in diabetic kidney via dampening NFκB activation, oxidative stress, and apoptosis.

nifuroxazidediabetic nephropathyrenal protectionNF-κB